Galapagos NV has initiated a Phase I trial for GLPG0492, its candidate drug for cachexia (loss of weight and muscle mass) and potentially other indications, such as Duchenne muscular dystrophy. The primary endpoints of the trial will be to determine the safety, tolerability and pharmacokinetics of GLPG0492. The double-blind, single ascending dose study will be conducted in 16 healthy human volunteers, with results expected in 2H10. GLPG0492 is an orally available small molecule developed i...